Synartro is a Swedish pharmaceutical company developing local injection treatments aiming to provide superior and sustained efficacy without systemic side-effects. This is achieved by combining our patented delivery technology with existing proven drugs.
Our pre-clinical lead program focuses on a novel therapy using our compound SYN321 for the treatment of osteoarthritis (OA). Currently this disease leaves up to 50% of patients without adequate pain relief.
Company Details
- Employees
- 6
- Founded
- -
- Address
- Stockholm, Se
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- synartro.se
- HQ
- Stockholm
Synartro Questions
Synartro's website is synartro.se
Synartro's LinkedIn profile is https://se.linkedin.com/company/synartro
Synartro has
6 employees.
View email and phone details for 6
employees at Synartro.
Synartro's industry is
Pharmaceutical Manufacturing
Synartro's top competitors are
Sciety,
Abego Pharma Insights Ab,
Bioarctic,
Elypta,
Sobi - Swedish Orphan Biovitrum Ab (Publ),
Biomimx® Srl,
Akiram Therapeutics,
Brisk Bioscience,
Sprint Bioscience,
Strike Pharma Ab.
Synartro's categories are Pharmaceutical Manufacturing
Synartro's founding year is 2011
